Inovio Pharmaceuticals Inc (INO.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|56||2011||Non-Executive Chairman of the Board|
|48||2009||President, Chief Executive Officer, Director|
|53||2002||Chief Financial Officer|
|49||2012||Chief Operating Officer|
|56||2010||Chief Medical Officer|
- BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
- BRIEF-Inovio Receives Milestone Payment From Medimmune
- BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China
- BRIEF-Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial
- BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results